Logo

Samsung Biologics Signs Multi-Product Development and Manufacturing Agreement with ImmuneOncia

Share this

Samsung Biologics Signs Multi-Product Development and Manufacturing Agreement with ImmuneOncia

Shots:

  • The two companies expand their 2018 agreement to develop and manufacture five candidates from ImmuneOncia's pipeline. The partners expand the collaboration to bring new treatments such as IMC-002 for cancer patients
  • Samsung Biologics to provide CDO services from cell line development- process development- non-clinical/clinical material manufacturing- to IND submission supporting the global clinical trials of five candidates
  • ImmuneOncia's portfolio consists of immune checkpoint Abs including IMC-002- a CD47-targeting Ab- currently evaluating in global P-I study based on IND approval obtained through the development and manufacturing partnership with Samsung Biologics

Click here to read full press release/ article | Ref: PRNewswire | Image: LinkedIn


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions